Maria Lacerca-Allen
Oficial de Cumplimiento en AIMMUNE THERAPEUTICS, INC. .
Fortuna: 4 595 $ al 30/04/2024
Cargos activos de Maria Lacerca-Allen
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SHIELD THERAPEUTICS PLC | Director/Miembro de la Junta | 10/05/2021 | - |
Independent Dir/Board Member | 10/05/2021 | - | |
AIMMUNE THERAPEUTICS, INC. | Oficial de Cumplimiento | 01/10/2020 | - |
American Red Cross Bay Area | Director/Miembro de la Junta | - | - |
Historial de carrera de Maria Lacerca-Allen
Antiguos cargos conocidos de Maria Lacerca-Allen.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ARTHROCARE CORPORATION | Director/Miembro de la Junta | 01/12/2013 | 29/05/2014 |
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Oficial de Cumplimiento | 17/12/2010 | 24/04/2014 |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | Consejero General | 14/09/2007 | 02/10/2007 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | Consejero General | 01/10/2007 | - |
Formación de Maria Lacerca-Allen.
University of California, Los Angeles | Graduate Degree |
Universidad de Buenos Aires | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 8 |
Argentina | 2 |
Irlanda | 2 |
Operativa
Director/Board Member | 3 |
General Counsel | 2 |
Graduate Degree | 2 |
Sectorial
Health Technology | 8 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
SHIELD THERAPEUTICS PLC | Health Technology |
Empresas privadas | 6 |
---|---|
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | Health Technology |
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | Health Technology |
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Arthrocare Corp.
Arthrocare Corp. Medical SpecialtiesHealth Technology ArthroCare Corp. manufactures medical devices for cardiovascular, spinal and other medical treatments. The company was founded on April 29, 1993 and is headquartered in Memphis, TN. | Health Technology |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
American Red Cross Bay Area |
- Bolsa de valores
- Insiders
- Maria Lacerca-Allen
- Experiencia